Videos

Heart Failure: Novel Therapies, Changing Biomarkers

Learn why NT-proBNP is the biomarker your lab should consider in congestive heart failure

Duration: 20 Minutes

Heart disease is the leading cause of death for both men and women. With the increased use of a novel therapy, ENTRESTO®, are we using the optimal biomarkers to accurately assess the risk and therapeutic response in patients taking this medication?

This promotional educational activity is brought to you by Ortho Clinical Diagnostics and is not certified for Continuing Medical Education (CME). The speakers are presenting on behalf of Ortho Clinical Diagnostics and must present information in accordance with applicable and/or local regulatory country requirements.

About Our Speaker:

About Our Speaker:

Jesse Earl Adams, III, MD

Adult Cardiologist, Director Cardiovascular CareBaptist Health, Louisville, KY

Legal Notice

By accessing, browsing, and/or using this website, you acknowledge that you have read, understood, and agree to be bound by QuidelOrtho’s Website Terms of Use, Privacy Notice and to comply with all applicable laws and regulations. If you do not agree to these terms, do not use the website. Additionally, the website contains information on products that is targeted to many different audiences and could contain product details or information otherwise not accessible or valid in your country. Product availability may vary from country to country and is subject to varying regulatory requirements. New QuidelOrtho branding may not be available in all markets, subject to country specific regulatory approval. Please be aware that we do not take any responsibility for your accessing such information that may not comply with any legal process, regulation, registration, or usage in the country of your origin.

QuidelOrtho Corporation
9975 Summers Ridge Road, San Diego, CA 92121, USA